Evidence map›Paper›PMID 39584050›Full record

ArticleAdvanced functional materials2024

Egg White Photocrosslinkable Hydrogels as Versatile Bioinks for Advanced Tissue Engineering Applications.

Mahboobeh Mahmoodi, Mohammad Ali Darabi, Neda Mohaghegh, Ahmet Erdem, Amir Ahari, Reza Abbasgholizadeh, Maryam Tavafoghi, Paria Mir Hashemian, Vahid Hosseini, Javed Iqbal and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced functional materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Mahboobeh MahmoodiTerasaki Institute for Biomedical Innovation, Los Angeles, California 90024, USA.
Mohammad Ali DarabiTerasaki Institute for Biomedical Innovation, Los Angeles, California 90024, USA.
Neda MohagheghTerasaki Institute for Biomedical Innovation, Los Angeles, California 90024, USA.
Ahmet ErdemCenter for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, California 90095, USA.
Amir AhariTerasaki Institute for Biomedical Innovation, Los Angeles, California 90024, USA.
Reza AbbasgholizadehTerasaki Institute for Biomedical Innovation, Los Angeles, California 90024, USA.
Maryam TavafoghiCenter for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, California 90095, USA.
Paria Mir HashemianDepartment of Biomedical Engineering, Boston University, Boston, Massachusetts, USA.
Vahid HosseiniTerasaki Institute for Biomedical Innovation, Los Angeles, California 90024, USA.
Javed IqbalCenter for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, California 90095, USA.
Reihaneh HaghniazTerasaki Institute for Biomedical Innovation, Los Angeles, California 90024, USA.
Hossein MontazerianCenter for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, California 90095, USA.
Jamileh JahangiryCenter for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, California 90095, USA.
Fatemeh NasrolahiCenter for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, California 90095, USA.
Arshia MirjafariCenter for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, California 90095, USA.
Erik PaganDepartment of Botany, Bacha Khan University, Charsadda, Khyber Pakhtunkhwa, Pakistan.
Mohsen AkbariTerasaki Institute for Biomedical Innovation, Los Angeles, California 90024, USA.
Hojae BaeDepartment of Stem Cell and Regenerative Biotechnology, KU Convergence Science and Technology Institute, Konkuk University, Seoul 05029, Republic of Korea.
Johnson V JohnTerasaki Institute for Biomedical Innovation, Los Angeles, California 90024, USA.
Hossein HeidariTerasaki Institute for Biomedical Innovation, Los Angeles, California 90024, USA.
Ali KhademhosseiniTerasaki Institute for Biomedical Innovation, Los Angeles, California 90024, USA.
Alireza Hassani NajafabadiTerasaki Institute for Biomedical Innovation, Los Angeles, California 90024, USA.

Funding

3D printed muscle-bone organ implant for treating large injuriesR01AR073135 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DOKMECI, MEHMET REMZI, JANG, HAE LIN · 2018 to 2022
$2.2M
NIAMS NIH HHS R01 AR073135
6 · The paper itself

Abstract

Three-dimensional (3D) bioprinting using photocrosslinkable hydrogels has gained considerable attention due to its versatility in various applications, including tissue engineering and drug delivery. Egg White (EW) is an organic biomaterial with excellent potential in tissue engineering. It provides abundant proteins, along with biocompatibility, bioactivity, adjustable mechanical properties, and intrinsic antiviral and antibacterial features. Here, we have developed a photocrosslinkable hydrogel derived from EW through methacryloyl modification, resulting in Egg White methacryloyl (EWMA). Upon exposure to UV light, synthesized EWMA becomes crosslinked, creating hydrogels with remarkable bioactivity. These hydrogels offer adjustable mechanical and physical properties compatible with most current bioprinters. The EWMA hydrogels closely resemble the native extracellular matrix (ECM) due to cell-binding and matrix metalloproteinase-responsive motifs inherent in EW. In addition, EWMA promotes cell growth and proliferation in 3D cultures. It facilitates vascularization when investigated with human umbilical vein endothelial cells (HUVECs), making it an attractive replacement for engineering hemocompatible vascular grafts and biomedical implants. In summary, the EWMA matrix enables the biofabrication of various living constructs. This breakthrough enhances the development of physiologically relevant 3D

Indexed as

3D BioprintingBioinkEgg whiteEndothelializationHydrogelsMethacryloylPhotocrosslinking

Identifiers

PMID39584050
PMCPMC11583837

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.